OxThera

Sep 7, 2023

Companies Covered  Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., Pharmascience, Inc. Key Findings of the Market Report In 2021, a sizable portion of the distribution channel segment's revenue is anticipated to come from online and retail pharmacies. The dominance is attributable to the rise in retail and online pharmacies in nations like the United States, the United Kingdom, India, and others. A large variety of GLP-2-based pipeline items for short bowel syndrome is the primary reason for the GLP-2 segment's dominance. Hospital pharmacies are anticipated to occupy a sizable portion of the market due to the industry's growing need for cutting-edge medications to treat ailments like Crohn's disease, one of the leading causes of short bowel syndrome. Market Trends for Short Bowel Syndrome Over the past several years, small bowel syndrome has become more common everywhere. The rise in patients receiving whole parenteral nourishment can be blamed for this. Short bowel syndrome is predicted to have a prevalence of four cases per million and an incidence of three cases per million. The precise incidence of the illness is unknown, and it is assumed based on the number of persons receiving parenteral feeding. The rise in frequency and incidence of uncommon diseases is probably what will drive the global market's expansion. There are now many additional treatments being tested in clinical trials for the management of short bowel syndrome, and there are no approved medications for the illness worldwide. The market's best insights begin with a simple request – get your sample now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13346 Short Bowel Syndrome Market Regional Outlook Various reasons are propelling the growth of the short bowel syndrome market in different regions. These are: The expansion of the short bowel syndrome market in North America is being driven by the presence of a sizable patient pool embracing cutting-edge medications and needing new treatment alternatives. It is projected that the availability of a broad variety of pipeline items as well as the extended usage of authorized pharmaceuticals to treat adults as well as kids would support market growth in this area over the course of the projection period. Asia Pacific is predicted to have the most rapid CAGR throughout the projection period. The market expansion in this area is fueled by the direct participation of large companies, substantial investments in research and development for the creation of novel pharmaceuticals, and a growing emphasis on GLP-2-based medication clinical trials. Global Short Bowel Syndrome Market: Key Players Market players for short bowel syndrome are involved in regulatory approvals, the creation of new services, acquisitions, and joint ventures with other businesses. The short bowel syndrome market will probably grow internationally as a result of these tactics over the coming years. The following companies are well-known participants in the global short bowel syndrome market: Takeda Pharmaceutical Company Limited 2021 The FDA designated Apraglutide, a long-acting GLP-2 analog of the next generation being researched for uncommon gastrointestinal (GI) illnesses, as an orphan drug for the treatment of acute graft-versus-host disease (aGVHD). Receiving an allogeneic hematopoietic stem cell transplant can cause GVHD, a severe, uncommon illness in which the patient's healthy cells are attacked by the donor's immune cells. In the first quarter of 2022, VectivBio AG intends to start a phase 2 study testing Apraglutide for the treatment of aGVHD. Hanmi Pharm. Co. Ltd. 2021 Hanmi Pharm Co. Ltd. disclosed that the United States Food and Drug Administration has given LAPS GLP-2 Analog (HM15912), a treatment for short bowel syndrome, fast-track designation. With the use of the company's platform technology, called Labscovery, a novel biopharmaceutical called LAPS GLP-2 Analog is being created for short-bowel syndrome. The condition has a survival rate of under 50% and impairs children and teenagers' growth adversely. It affects around 24.5 out of every 100,000 infants. For Customization or Any Other Queries, Get in Touch with Our Industry Experts at - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=13346 Global Short Bowel Syndrome Market Segmentation Product About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports. Contact: